KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Total Current Liabilities (2019 - 2025)

Historic Total Current Liabilities for Royalty Pharma (RPRX) over the last 7 years, with Q4 2025 value amounting to $636.2 million.

  • Royalty Pharma's Total Current Liabilities fell 4924.99% to $636.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $636.2 million, marking a year-over-year decrease of 4924.99%. This contributed to the annual value of $636.2 million for FY2025, which is 4924.99% down from last year.
  • Per Royalty Pharma's latest filing, its Total Current Liabilities stood at $636.2 million for Q4 2025, which was down 4924.99% from $530.8 million recorded in Q3 2025.
  • Over the past 5 years, Royalty Pharma's Total Current Liabilities peaked at $1.3 billion during Q4 2024, and registered a low of $124.6 million during Q1 2024.
  • For the 5-year period, Royalty Pharma's Total Current Liabilities averaged around $627.0 million, with its median value being $407.4 million (2021).
  • Its Total Current Liabilities has fluctuated over the past 5 years, first plummeted by 8884.62% in 2024, then skyrocketed by 84951.76% in 2025.
  • Royalty Pharma's Total Current Liabilities (Quarter) stood at $171.2 million in 2021, then surged by 581.33% to $1.2 billion in 2022, then plummeted by 86.17% to $161.4 million in 2023, then soared by 676.82% to $1.3 billion in 2024, then crashed by 49.25% to $636.2 million in 2025.
  • Its Total Current Liabilities stands at $636.2 million for Q4 2025, versus $530.8 million for Q3 2025 and $1.2 billion for Q2 2025.